Linaclotide for functional constipation in paediatric patients: phase III results

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2024-02-12 DOI:10.1038/s41575-024-00903-6

Jordan Hindson

引用次数: 0

查看原文本刊更多论文

利那洛肽治疗儿科功能性便秘：III 期研究结果

利那洛肽是一种鸟苷酸环化酶 C 激动剂，用于治疗成人慢性特发性便秘。一项随机、多中心 III 期试验评估了利那洛肽在功能性便秘儿科患者中的使用情况。330名患者（6-17岁）被随机分配接受口服利那洛肽（72微克）或安慰剂，每天一次，为期12周。与安慰剂相比，利那洛肽组患者的自发性排便次数有明显改善。该疗法的耐受性良好，美国食品及药物管理局已批准利那洛肽用于治疗6-17岁患者的功能性便秘。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.